Fars News Agency :: Iranian Scientist Discovers Protein Generating Plaque in Cardiovascular System
TEHRAN (FNA)- Nima Aqili, an Iranian cardiologist, reported that he has discovered a protein responsible for the generation of plaques in the cardiovascular system, a breakthrough which can help patients with heart artery congestion.
"In researches on animals, the protein effective in the generation of cardiovascular plaques was discovered," Dr. Aqili, an Iranian cardiologist who works for one of Boston's main hospitals in the US, told FNA in Tehran on Tuesday.
He said that the first stage of the research has been accomplished and he and his colleagues have found a protein named NPY which produces plaques in the cardiovascular system.
Dr. Aqili underlined that the discovery can lead to the production of a medicine for cardiac patients who suffer from artery congestion.
Iranian scientists have made giant advancements in different fields.
In September, Iranian scientists developed and produced a new type of medication for the treatment of heart failure, breaking the US and Israel's monopoly in the field.
"The heart or brain vessels are blocked by blood clots after a heart attack and the medicine can dissolve the blood clots and open the blood vessels immediately," President of Isfahan Pharmaceutical Company Abolfazl Mostafavi told FNA in September.
He said that the drug named ATP is not a chemical compound but an enzyme which exists in the body of everyone.
By producing this medicine, Iran could break the US and Israel's monopoly in the production of this specific kind of drug, Mostafavi underlined.
Iranian scientists had also earlier this year managed to break Israel's monopoly by producing a new MS drug which makes Iranian patients needless of foreign medicines.
"Fortunately, the production monopoly on the drug was broken by Iran's pharmaceutical industries and is now being distributed in our country's drug market," Iranian Deputy Health Minister for Food and Drugs Affairs Ebrahim Sheibani said in August.
He also reiterated that the drug can be used even during pregnancy by ready-made injection syringe technology.
Also, Iran shattered the United States' monopoly in the production of the most important drugs in the treatment of MS in 2007.
Interferon beta 1, generically known as Ziferon, is mainly injected subcutaneously and has antiviral and immunomodulating properties. The drug is mainly used in the management of multiple sclerosis, although its mode of action is unclear.
Iran has also introduced two other home-made MS drugs, namely Resigene (interferon beta 1a) and Cinnovex, in the last few years.
The Center for Pharmaceutical Products has already produced five biotechnological drugs, making Ziferon the sixth medication produced by the company.
TEHRAN (FNA)- Nima Aqili, an Iranian cardiologist, reported that he has discovered a protein responsible for the generation of plaques in the cardiovascular system, a breakthrough which can help patients with heart artery congestion.
"In researches on animals, the protein effective in the generation of cardiovascular plaques was discovered," Dr. Aqili, an Iranian cardiologist who works for one of Boston's main hospitals in the US, told FNA in Tehran on Tuesday.
He said that the first stage of the research has been accomplished and he and his colleagues have found a protein named NPY which produces plaques in the cardiovascular system.
Dr. Aqili underlined that the discovery can lead to the production of a medicine for cardiac patients who suffer from artery congestion.
Iranian scientists have made giant advancements in different fields.
In September, Iranian scientists developed and produced a new type of medication for the treatment of heart failure, breaking the US and Israel's monopoly in the field.
"The heart or brain vessels are blocked by blood clots after a heart attack and the medicine can dissolve the blood clots and open the blood vessels immediately," President of Isfahan Pharmaceutical Company Abolfazl Mostafavi told FNA in September.
He said that the drug named ATP is not a chemical compound but an enzyme which exists in the body of everyone.
By producing this medicine, Iran could break the US and Israel's monopoly in the production of this specific kind of drug, Mostafavi underlined.
Iranian scientists had also earlier this year managed to break Israel's monopoly by producing a new MS drug which makes Iranian patients needless of foreign medicines.
"Fortunately, the production monopoly on the drug was broken by Iran's pharmaceutical industries and is now being distributed in our country's drug market," Iranian Deputy Health Minister for Food and Drugs Affairs Ebrahim Sheibani said in August.
He also reiterated that the drug can be used even during pregnancy by ready-made injection syringe technology.
Also, Iran shattered the United States' monopoly in the production of the most important drugs in the treatment of MS in 2007.
Interferon beta 1, generically known as Ziferon, is mainly injected subcutaneously and has antiviral and immunomodulating properties. The drug is mainly used in the management of multiple sclerosis, although its mode of action is unclear.
Iran has also introduced two other home-made MS drugs, namely Resigene (interferon beta 1a) and Cinnovex, in the last few years.
The Center for Pharmaceutical Products has already produced five biotechnological drugs, making Ziferon the sixth medication produced by the company.
I think you friends have been lying to me again.
